BACKGROUND: NSAIDs are widely used to treat fever and pain in children, but their possible role in the progression of some bacterial infections is controversial. OBJECTIVE: This study was performed to analyse reported cases of severe bacterial infection associated with NSAID exposure in children admitted for this reason to a general paediatric department. METHODS: This study was based on the reporting system of hospital admissions for severe bacterial infections in children after NSAID exposure, and followed the recommendations of the European Guidelines of Pharmacovigilance for medicines used in a paediatric population. Data were prospectively collected and reported by active daily surveillance in the department from November 2002 to November 2005. RESULTS: Thirty-two cases of severe bacterial infections (cellulitis, soft tissue abscesses, parapneumonic empyema, necrotizing pneumonia, adenophlegmon [fever and a tender, warm and easily compressible neck mass] and lateral or retropharyngeal abscesses) were identified in children who had received NSAIDs, principally ibuprofen, in an exposure window of 15 days before the beginning of the signs of infection. Staphylococcus aureus, group A streptococci and Streptococcus pneumoniae were identified. Seven (22%) children required surgical treatment, and four (13%) were hospitalized in an intensive care unit. CONCLUSIONS: The frequency of hospitalization for severe bacterial infection as a possible adverse effect of NSAID use was 0.6% (95% CI 0.4, 0.9) of all admissions during the study period. The frequency of severe bacterial infections after exposure to NSAIDs was elevated (one case per month) in the department studied. Further work is necessary to confirm these findings, given the potential for recruitment and protopathic biases in our study.
BACKGROUND: NSAIDs are widely used to treat fever and pain in children, but their possible role in the progression of some bacterial infections is controversial. OBJECTIVE: This study was performed to analyse reported cases of severe bacterial infection associated with NSAID exposure in children admitted for this reason to a general paediatric department. METHODS: This study was based on the reporting system of hospital admissions for severe bacterial infections in children after NSAID exposure, and followed the recommendations of the European Guidelines of Pharmacovigilance for medicines used in a paediatric population. Data were prospectively collected and reported by active daily surveillance in the department from November 2002 to November 2005. RESULTS: Thirty-two cases of severe bacterial infections (cellulitis, soft tissue abscesses, parapneumonic empyema, necrotizing pneumonia, adenophlegmon [fever and a tender, warm and easily compressible neck mass] and lateral or retropharyngeal abscesses) were identified in children who had received NSAIDs, principally ibuprofen, in an exposure window of 15 days before the beginning of the signs of infection. Staphylococcus aureus, group A streptococci and Streptococcus pneumoniae were identified. Seven (22%) children required surgical treatment, and four (13%) were hospitalized in an intensive care unit. CONCLUSIONS: The frequency of hospitalization for severe bacterial infection as a possible adverse effect of NSAID use was 0.6% (95% CI 0.4, 0.9) of all admissions during the study period. The frequency of severe bacterial infections after exposure to NSAIDs was elevated (one case per month) in the department studied. Further work is necessary to confirm these findings, given the potential for recruitment and protopathic biases in our study.
Authors: Carrie L Byington; LaShonda Y Spencer; Timothy A Johnson; Andrew T Pavia; Daniel Allen; Edward O Mason; Sheldon Kaplan; Karen C Carroll; Judy A Daly; John C Christenson; Matthew H Samore Journal: Clin Infect Dis Date: 2002-01-03 Impact factor: 9.079
Authors: Stephanie M Hamilton; Clifford R Bayer; Dennis L Stevens; Richard L Lieber; Amy E Bryant Journal: J Infect Dis Date: 2008-12-01 Impact factor: 5.226
Authors: Stephanie H Factor; Orin S Levine; Lee H Harrison; Monica M Farley; Allison McGeer; Tami Skoff; Carolyn Wright; Benjamin Schwartz; Anne Schuchat Journal: Emerg Infect Dis Date: 2005-07 Impact factor: 6.883
Authors: D Lepelletier; V Pinaud; P Le Conte; C Bourigault; N Asseray; F Ballereau; J Caillon; C Ferron; C Righini; E Batard; G Potel Journal: Eur J Clin Microbiol Infect Dis Date: 2016-03-04 Impact factor: 3.267
Authors: D Lepelletier; V Pinaud; P Le Conte; C Bourigault; N Asseray; F Ballereau; J Caillon; C Ferron; C Righini; E Batard; G Potel Journal: Eur J Clin Microbiol Infect Dis Date: 2016-09-07 Impact factor: 3.267
Authors: Victoria C Ziesenitz; Tatjana Welzel; Madelé van Dyk; Patrick Saur; Matthias Gorenflo; Johannes N van den Anker Journal: Paediatr Drugs Date: 2022-09-02 Impact factor: 3.930
Authors: Maurizio de Martino; Alberto Chiarugi; Attilio Boner; Giovanni Montini; Gianluigi L De' Angelis Journal: Drugs Date: 2017-08 Impact factor: 9.546
Authors: Amy E Bryant; Michael J Aldape; Clifford R Bayer; Eva J Katahira; Laura Bond; Carrie D Nicora; Thomas L Fillmore; Therese R W Clauss; Thomas O Metz; Bobbie-Jo Webb-Robertson; Dennis L Stevens Journal: PLoS One Date: 2017-02-28 Impact factor: 3.240
Authors: Outi Hälli; Minna Haimi-Hakala; Tapio Laurila; Claudio Oliviero; Elina Viitasaari; Toomas Orro; Olli Peltoniemi; Mika Scheinin; Saija Sirén; Anna Valros; Mari Heinonen Journal: Porcine Health Manag Date: 2018-03-06